Document is current
Any future updates will be listed below
-
Authors
Baek, Amy E.
Nelson, Erik R.
-
Funding
Funding for this research was provided by:
National Cancer Institute (R00CA172357)
- License Information
-
More Information
Article History
Received: 20 December 2015
Accepted: 17 March 2016
First Online: 28 March 2016
Compliance with Ethical Standards
:
: Amy E. Baek declares no conflict of interest.Erik R. Nelson is the co-inventor of patent WO2015065505 A1, “Use of CYP27A1 inhibitors, statin, or LXR antagonists alone or in combination with conventional therapy for the treatment of breast cancer.”
Free to read: This content has been made available to all.
